Cepheid Shares Spike on Analyst Upgrade | GenomeWeb

NEW YORK (GenomeWeb News) – Shares in Cepheid have climbed more than 8 percent today following a morning upgrade of the company's stock by an analyst with William Blair & Co.

Analyst Brian Weinstein upgraded Cepheid shares to "outperform" from "market perform," noting expected revenues from new diagnostic products and increased hospital spending in 2010.

In afternoon trading on Nasdaq, Cepheid's shares had risen 8.3 percent to $15.58 from $14.38 at close of market on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.